Skip to content
Thursday, November 12, 2026
Chipza Platform

America and Britain Establish Zero-Tariff Arrangement on Medicines.

Drug exports between the United States and United Kingdom
Representative image of drug shipments.

The UK and US have signed a major commercial pact that will keep no import taxes on UK pharmaceutical exports being sold in the US market.

Agreement Details of the Accord

Under the terms of the agreement, the UK has committed to boost expenditure on medicines through the public health system. This move ensures that duties on these crucial goods will stay at nothing for a period of three years.

This development comes after previous warnings to hike tariffs on branded drug imports, with increases discussed up to one hundred percent.

"This agreement between the United Kingdom strengthens the international landscape for new treatments and establishes long-overdue equity to U.S.–U.K. pharmaceutical trade," a release noted.

Trade Importance

Pharmaceuticals represent one of the Britain's biggest goods shipped to the America, which is by far the primary market for major British pharmaceutical firms.

Statistics show that in the 12 months leading up to September, the UK shipped medicines worth billions to the US. This figure made up 17.4% of all goods exports in that timeframe.

"This guarantee safeguards jobs, increases investment and sets the stage for the UK to establish itself as a worldwide center for medical research," a government official stated.

Key NHS Changes

The deal involves several notable changes from the UK:

  • Revised Affordability Limit: The UK will increase the affordability limit at which it judges new medicines to be unaffordable by a quarter.
  • Boosted Medicine Funding: There is a target to double overall public funding on medicines from 0.3% of Gross Domestic Product to 0.6 percent over the following ten-year period.
  • Payback Limit: The percentage drug companies must return to the NHS to stay within budget will be limited at 15%. Previously, repayments topped 20%.

Industry Background

The deal follows a protracted dispute between the pharmaceutical industry and the UK government over medicine costs and regulatory access.

This friction were heightened by arguments that American patients were paying several times more for the same drugs than consumers in the Britain and the EU.

Recently, several large pharmaceutical investments in the UK have been delayed or abandoned, while major investments have been directed toward American operations.

The Science Minister publicly accepted that the NHS had to spend more on drugs, noting that its spending on drugs had decreased as a share of its total funding over the past decade.

SD
Written by

Sandra Davis

A tech journalist and startup advisor with over a decade of experience covering UK innovation and digital transformation trends.

Chipza Platform

Type to search articles.